Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5579 Target Snapshot

Citron Rho-interacting kinase · SINGLE PROTEIN · Homo sapiens

574Compounds
143Assays
13Approved Drugs
463.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O14578. Use UniProt O14578 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O14578 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Citron Rho-interacting kinase as ChEMBL target CHEMBL5579, mapped to UniProt O14578. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Citron Rho-interacting kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5579
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14578
Citron Rho-interacting kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Citron Rho-interacting kinase is the right protein anchor across sources, using UniProt O14578 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCitron Rho-interacting kinase
UniProt AccessionO14578
Component TypeProtein
Sequence Length2027 aa

Citron Rho-interacting kinase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Citron Rho-interacting kinase, mapped to UniProt O14578. Sequence length is 2027 aa.

Mapped IDO14578
Review nameCitron Rho-interacting kinase
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

13
Approved
9
Phase III
10
Phase II
11
Phase I
Assay Mix

Activity Type Distribution

IC5082.0
KI5.0
KD376.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5572737 9.52 Kd 0.3 Preclinical
CHEMBL400402 8.52 Kd 3.0 Preclinical
CHEMBL5591534 8.26 IC50 5.5 Preclinical
CHEMBL5568742 8.0 IC50 10.0 Preclinical
CHEMBL5572737 7.92 IC50 12.0 Preclinical
CHEMBL5595104 7.89 IC50 13.0 Preclinical
CHEMBL379218 7.89 Kd 13.0 Preclinical
CHEMBL5575901 7.85 IC50 14.0 Preclinical
CHEMBL5569359 7.82 IC50 15.0 Preclinical
CHEMBL5579704 7.8 IC50 16.0 Preclinical
Distribution

pChEMBL Value Distribution

20
5.0
28
5.5
33
6.0
21
6.5
31
7.0
15
7.5
4
8.0
1
8.5
0
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
FEDRATINIB
CHEMBL1287853
Approved 2019
ABEMACICLIB
CHEMBL3301610
Approved 2017
ERLOTINIB
CHEMBL553
Approved 2004
Assay Landscape

Assay Landscape

143
Total Assays
129
Tested Compounds
1
Assay Types
Binding — 143 assays, 129 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 111 106 6.6
assay format 25 1 5.6
cell-based format 6 3 7.5
subcellular format 1 19 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine